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Abstract
Breast cancer patients show a wide variation in normal tissue reactions after radiotherapy. The
individual sensitivity to x-rays limits the efficiency of the therapy. Prediction of individual sensitivity
to radiotherapy could help to select the radiation protocol and to improve treatment results. The
aim of this study was to assess the relationship between gene expression profiles of ex vivo un-
irradiated and irradiated lymphocytes and the development of toxicity due to high-dose
hyperfractionated radiotherapy in patients with locally advanced breast cancer. Raw data from
microarray experiments were uploaded to the Gene Expression Omnibus Database http://
www.ncbi.nlm.nih.gov/geo/ (GEO accession GSE15341). We obtained a small group of 81 genes
significantly regulated by radiotherapy, lumped in 50 relevant pathways. Using ANOVA and t-test
statistical tools we found 20 and 26 constitutive genes (0 Gy) that segregate patients with and
without acute and late toxicity, respectively. Non-supervised hierarchical clustering was used for
the visualization of results. Six and 9 pathways were significantly regulated respectively. Concerning
to irradiated lymphocytes (2 Gy), we founded 29 genes that separate patients with acute toxicity
and without it. Those genes were gathered in 4 significant pathways. We could not identify a set of
genes that segregates patients with and without late toxicity. In conclusion, we have found an
association between the constitutive gene expression profile of peripheral blood lymphocytes and
the development of acute and late toxicity in consecutive, unselected patients. These observations
suggest the possibility of predicting normal tissue response to irradiation in high-dose non-
conventional radiation therapy regimens. Prospective studies with higher number of patients are
needed to validate these preliminary results.
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Radiation is an effective therapy in patients with local
advanced breast cancer (LABC) [1,2]. Tumor control by
radiotherapy (RT) requires the use of maximum dose that
can be delivered while maintaining a tolerance risk of nor-
mal tissue toxicity [3]. Better local control outcomes with
an acceptable toxicity have been obtained by using high
total doses radiation administered in two small fractions
per day compared with standard RT protocols [4]. Some
patients treated with RT will develop early or late reactions
limiting the efficacy of RT. Knowledge of individual varia-
tions of normal tissue toxicities determining tolerance
would be of great value in patients treated with high-dose
radiation protocol [5]. Microarray technology is a high
throughput method that allows large scale genomic stud-
ies. Because intrinsic radiosensitivity is genetically deter-
mined, different cells from the patient can be used to
measure sensitivity to radiation [6]. Few studies have been
published with regard to radiation induced toxicity and
microarrays [2,7-10]. Patients were previously selected
according to the clinical toxicity observed and only three
publications included breast cancer patients [see Addi-
tional file 1].
The aim of this study was to assess the relation of the gene
expression profile from un-irradiated and irradiated lym-
phocytes and the development of toxicity due to RT in
patients with LABC.
Patients and methods
Twelve consecutive patients treated between 1991 and
1997 by a hyperfractionated dose-escalation radiation
therapy schedule at the Hospital Dr. Negrín suffering from
LABC were prospectively recruited and inform consent
was given. The study was approved by the Research and
Ethics Committee of our institution. Blood samples were
extracted and tested during 2005 and follow up was
closed on December 2008. Characteristics of the patients
are shown in Table 1. Early toxicity was evaluated during
and at the end of RT, and late toxicity was evaluated at 6-
month follow-up examination. The RTOG morbidity
score system was used to classify the toxicity of patients
into three levels: grades 1, 2 and 3–4 (Table 2). All
patients were referred to recieve 60 Gy to the whole breast
over a period of 5 weeks in two daily fractions of 1.2 Gy
separated by at least 6 h on 5 days each week, and fol-
lowed by a boost of 21.6 Gy to a total dose of 81.6 Gy.
Culture of lymphocytes and radiation protocol details
were previously reported [11]. Twenty four independent
hybridizations were performed to compare lymphocytes
from twelve patients, before and after 2 Gy irradiation,
against a human RNA universal control. A microarray
containing 35.327 human 70-mer oligo probe sets, pro-
duced at the SweGene DNA Microarray Resource Center
(Lund University, Sweden) was used. Array scanning,
image analysis and data normalization were performed as
previously described [12,13]. Identification of differen-
tially-expressed genes was performed using the SAM (Sig-
nificance Analysis for Microarrays) statistical technique
[14]. A q value was assigned for each of the detectable
genes in the array measuring the lowest false discovery
rate (FDR). Genes with a FDR of less than 10% were con-
sidered to present significant differential expression. Thus,
we studied gene expression profile of lymphocytes treated
with 0 and 2 Gy separately. To explore genes modulated
by radiation, we also compared gene expression profiles
of lymphocytes treated with 0 versus 2 Gy. T-test and
ANOVA test [15,16] were used to compare the set of genes
significantly regulated, in un-irradiated and in 2 Gy-irradi-
ated lymphocytes, with toxicity. Non-supervised hierar-
chical clustering [17] was made using MultiExperiment
Viewer (The Institute for Genomic Research, http://
www.tigr.org/tdb/microarray/). A genetic signature that
could separate toxicity and non toxicity in a constitutive
and in a modulated-by-radiation way was performed (Fig-
ure 1). Functional classification and pathway analysis of
expressed genes were performed by using the web-based
tools Onto-Express (OE) and Pathway-Express (PE)
Experimental designFigu e 1
Experimental design. RNA from lymphocytes treated 
with 0 and 2 Gy dose of radiation were compared against a 
human universal RNA. SAM analyses were performed to dis-
close significant regulated genes in these two ways. In order 
to explore genes modulated by radiation, a two-class paired 
test was performed using SAM. To discriminate genes that 
could be significantly associated with RT toxicity, non-super-
vised hierarchical clustering, in MeV, was used to visualize 
the whole set of significant genes modulated before and after 
X-ray exposure in patients with and without acute/late toxic-
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Wayne University, Detroit, MI. http://vor
tex.cs.wayne.edu) [18,19]. OE classify genes in order to
biological process (BP), cellular component and molecu-
lar function, and it is able to estimate statistical differences
between different gene ontology terms [20]. PE is based
on a novel method that uses a system biology approach
that includes important biological factors that describes
how these genes interacts and the type of signaling inter-
actions between them [21,22].
Results
Comparison of gene expression profiles from 0 Gy and 2
Gy-treated lymphocytes, using two-class paired test in
SAM program, identified a total of 81 genes significantly
regulated by RT [see Additional file 2]. We could not clus-
ter these genes in order to segregate patients with acute or
late toxicity. PE was used to explore biological pathways
significantly regulated by radiation. Fifty seven genes were
mapped and PE identified 50 pathways significantly regu-
lated (p < 0.01). Among the RT modulated pathways there
were cell cycle, nucleotide excision repair, DNA replica-
tion, mismatch repair; MAPK, erbB, and VEGF signaling,
ubiquitination mediated proteolysis, notch and Wnt [see
Additional file 3]. A functional classification of 81 regu-
lated genes was made using OE. Forty-five genes were clas-
sified according to the BP and several processes were
modified by RT [see Additional file 4].
SAM analysis from un-irradiated lymphocytes revealed
7391 constitutive regulated genes. ANOVA test in MeV
identified 20 genes that segregated patients with grade 1,
from grade 2 and grade 3–4 acute toxicity (p < 0.01) (Fig-
ure 2). PE identified 6 pathways significantly regulated (p
< 0.01): protein export, regulation of autophagy, vibrio
cholerae infection, phosphatidylinositol signaling system,
focal adhesion and regulation of actin cytoskeleton [see
Additional file 5]. OE classified 14 genes according to the
BP. Processes as chromatin remodeling, regulation of
endothelial cell proliferation, oxidation reduction and
cellular respiration were constitutively modulated (p <
0.05) [see Additional file 6]. The same strategy was fol-
lowed for late toxicity. T-test identified 26 genes that con-
stitutively segregated patients who suffered severe late
toxicity from patients who did not (p < 0.01) (Figure 2).
PE identified 9 pathways significantly regulated (p <
0.01): regulation of actin cytoskeleton, MAPK signaling,
epithelial cell signaling in helicobacter, Erb B signaling
pathway, renal cell carcinoma, natural killer cell mediated
cytotoxicity, T cell receptor signaling, axon quidance and
focal adhesion [see Additional file 5]. The role of PAK1
(p21-Cdc42/Rac)-activated kinase 1 must be highlighted
since it was involved in all the 9 pathways. OE scored 13
genes according to the BP. Processes significantly regu-
lated (p < 0.05) were: lipid, cholesterol and sterol-biosyn-
thetic processes, cytoskeleton organization and
biogenesis, positive regulation of gene specific transcrip-
tion, hair follicle development, ER-nuclear signaling path-
way, positive regulation of JNK activity and others [see
Additional file 7].
Lymphocytes from patients were also irradiated at 2 Gy
dose. SAM identified 7393 genes significantly regulated.
ANOVA test (p < 0.01) identified 29 genes that separated
patients with grade 1, from grade 2 and grade 3–4 acute
toxicity (Figure 3). We did not observe common genes
between this set of genes and those corresponding to un-
Table 1: Characteristics of the patients included in the study. 
Age, menopause status, characteristics of the tumor and 
systemic treatment were added.
Characteristic n %
Age
<60 years 5 41.7






















Hormonal therapy 1 8.3
Chemotherapy-hormonal therapy 10 83.4
Table 2: Grade of acute and late toxicity of patients included in 
the study.
Patient Code Age Acute Toxicity Late Toxicity
1 01 34 Grade 1 Grade 2
2 02 60 Grade 1 Grade 3
3 03 47 Grade 1 Grade 2
4 04 68 Grade 2 Grade 2
5 05 67 Grade 2 Grade 3
6 06 70 Grade 2 Grade 2
7 07 63 Grade 2 Grade 3
8 08 72 Grade 2 Grade 3
9 09 57 Grade 3 Grade 3
10 10 64 Grade 3 Grade 3
11 11 47 Grade 3 Grade 2
12 12 53 Grade 4 Grade 4
Age is shown.Page 3 of 7
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Non-supervised hierarchical clustering of constituve genes regulated in un-irradiated lymphocytesFigure 2
Non-supervised hierarchical clustering of constituve genes regulated in un-irradiated lymphocytes. Clustering 
used Euclidean distance correlation and average linkage, and was processed and displayed with MultiExperiment Viewer http://
www.tigr.org/tdb/microarray/. Upper panel shows a 20 gene set that segregated patients with different grade of acute toxicity 
(First three patients, grade 1; next five patients, grade 2; last four patients, grades 3–4) ANOVA test, p < 0.01. Lower panel 
shows a 26 gene set that segregated patients with different grade of late toxicity (First five patients, grade 2; last seven patients, 
grades 3–4) T-test, p < 0.01. The dendogram to the left of the heat map shows clustering of the genes. Accession number, gene 
symbol, gene description and fold change were added. Colour boxes indicate the biological process of each gene.
Radiation Oncology 2009, 4:17 http://www.ro-journal.com/content/4/1/17irradiated lymphocytes (constitutive genes). PE identified
4 significantly regulated pathways (p < 0.01): phosphati-
dylinositol signaling system, regulation of actin cytoskel-
eton, cell cycle and TGF-beta signaling pathway [see
Additional file 5]. OE scored 15 genes according to BP
with some processes also significantly regulated [see Addi-
tional file 8]. We could not obtain a consistent set of genes
able to separate patients with regard to late toxicity in irra-
diated lymphocytes (Table 3).
Discussion
Constitutive gene expression pattern from un-irradiated
lymphocytes can segregates LABC patients with acute and
late toxicity from patients without toxicity after hyperfrac-
tionated radiation therapy treatment. Using 2 Gy irradi-
ated lymphocytes from the same patients we could only
observe association related to acute toxicity. Few series
were published to explore the relation of radiation
induced toxicity and microarray, and only three were
referred to breast cancer [7,9,10]. The paper published by
Svensson et al. is similar to the present work in relation to
the experimental design, but was assessed in prostate can-
cer patients [2]. Recently, Rødningen et al. published two
relevant papers [10,23]. Our results were not similar
related to genes involved in late toxicity. Anyhow, we
coincided in relation to some BP. Differences in cell type,
microarray platform, experimental design, RT protocol
and statistical strategy could explain those differences.
Compared with previously available studies, this is the
first work in which: i) patients were consecutive and non-
Non-supervised hierarchical clustering of genes regulated in irradiated lymphocytes (2 Gy)Figure 3
Non-supervised hierarchical clustering of genes regulated in irradiated lymphocytes (2 Gy). Clustering used Eucli-
dean distance correlation and average linkage, and was processed and displayed with MultiExperiment Viewer http://
www.tigr.org/tdb/microarray/. A 29 gene set segregated patients with different grades of acute toxicity (First three patients, 
grade 1; next five patients, grade 2; last four patients, grades 3–4) ANOVA test, p < 0.01. The dendogram to the left of the heat 
map shows clustering of the genes. Accession number, gene symbol, gene description and fold change were added. Colour 
boxes indicate the biological process of each gene.Page 5 of 7
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dose radiation protocol with altered fractionation, iii) the
complete human genome was analyzed and iv) compara-
tive studies of constitutive gene expression profiles of
LABC patients and toxicity were made.
Pak1 seems to have an important role in late toxicity in
our study. Pak1 overexpression is related to apoptosis-
resistance in normal and tumour cells [24]. An appropri-
ate apoptotic response seems to protect normal tissue
against radiation late toxicity [25]. Therefore, over-expres-
sion of Pak1 observed in our patients would be related to
resistance to late toxicity. The role of PAK1 in late toxicity
should be explored.
This long term study makes a novel contribution to shed
light to the relationship between the constitutive gene
expression profile of peripheral blood lymphocytes and
toxicity after RT. This analysis opens the possibility that
the different constitutive expression levels of a selected
group of genes would predict acute and late toxicity
caused by RT. The feasibility and cost effectiveness of this
assay would encourage clinical application in larger series
of patients. Further prospective experiments are needed to
validate those genomic profiles.
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Additional file 1
Studies that have applied microarray analysis to compare gene expres-
sion profiles in patients with severe versus mild normal tissue damage 
after radiotherapy. Brief summary of studies related to radiotherapy and 
microarrays. The table includes the author's name and the year of publi-
cation, the cell type used the tumour type, some characteristics of the study 
and the most relevant findings.




Genes significantly regulated by radiotherapy in human lymphocytes. 
Eighty one genes regulated by radiation. The table contains gene symbol, 
description, numerator, fold change, q value, gene id, transcript id, Ref-
Seq, description RefSeq and GeneBank Acc number.




Pathways significantly regulated by radiotherapy in human lym-
phocytes. Fifty pathways regulated by radiation. The table contains rank, 
database name, pathway name, impact factor, genes in pathway, input 
genes in pathway, pathway genes on chip and p value.




Functional Classification. Genes modulated by radiotherapy. The table 
contains the functional classification in relation to biological process of 81 
genes modulated by radiotherapy.




Canonical pathways that were significantly modulated in the differ-
ent set of genes. Pathways modulated and related to acute and late tox-
icity, 0 and 2 Gy. Pathway name, p-value, gene name and GeneBank 
accession number were included.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1748-
717X-4-17-S5.doc]
Table 3: Summary of results obtained after non-supervised 
hierarchical clustering.
Group Association Gene Set N° of pathways
Acute 0 Gy Y 20 6
Late 0 Gy Y 26 9
Acute 2 Gy Y 29 4
Late 2 Gy N 11 -
"Y" indicates positive association between toxicity and gene 
expression. "N" indicates no association. The number of genes 
associated for each group were included, as well as the number of 
significant pathways derived from the gene sets.Page 6 of 7
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Functional Classification. Acute toxicity, 0 Gy. The table contains the 
functional classification in relation to biological process of genes regulated 
in un-irradiated lymphocytes and involved in acute toxicity.




Functional Classification. Late toxicity, 0 Gy. The table contains the 
functional classification in relation to biological process of genes regulated 
in un-irradiated lymphocytes and involved in late toxicity.
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functional classification in relation to biological process of genes regulated 
in irradiated lymphocytes and involved in acute toxicity.
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